Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023)

Bioventus (BVS) posted Cash from Discontinued Operations of 2169000.0 for Q2 2023, down 70.65% on a QoQ basis from 1271000.0 in Q4 2022.

Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends

Bioventus' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 2169000.0 for Q2 2023.

Quarterly Cash from Discontinued Operations changed N/A year-over-year to 2169000.0 in Q2 2023, while the trailing twelve-month figure through Dec 2023 was 2169000.0 (down 1.83% YoY) and the FY2023 annual result came in at 2169000.0, down 1.83% from the prior year.
Cash from Discontinued Operations was 2169000.0 for Q2 2023 at Bioventus, down from 1271000.0 in the prior quarter.
Across five years, Cash from Discontinued Operations topped out at 859000.0 in Q4 2022 and bottomed at 2169000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Discontinued Operations (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	-
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	-
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	-
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	-
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	-
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	-
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	-
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	-
10	Bioventus	837.84 Mn	801.99 Mn	90.77 Mn	-

Download Data